YIH
CASI

Y-Intercept (HK)’s CASI Pharmaceuticals CASI Stock Holding History

Y-Intercept (HK)’s Portfolio CASI Stock Details CASI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,625
Closed -$25K – 665
2021
Q2 		$25K Buy
+1,625
New +$27.3K 0.01% 577

Other funds holding CASI

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
IACGFIA
IDG-Accel China Growth Fund III Associates Hong Kong $31.2M AUM 2.97% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WSCM
Wellington Shields Capital Management New York $788M AUM 66.95% 1-Year Est. Return
WSC
Wellington Shields & Co New York $446M AUM 38.92% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Y-Intercept (HK)'s CASI Position: Q3 2021 in Review

Y-Intercept (HK) sold out of CASI Pharmaceuticals (CASI) in Q3 2021, closing a stake of 1,625 shares — an estimated $25K sold.

Y-Intercept (HK) first reported a position in CASI in Q2 2021 and held it in 1 quarter. The position peaked at $25K in Q2 2021. 58 funds tracked by Wall St. Rank hold CASI as of Q3 2021.

  • Y-Intercept (HK) reported no remaining CASI Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Y-Intercept (HK) sold 1,625 CASI Pharmaceuticals shares in Q3 2021, an estimated $25K.
  • Y-Intercept (HK) first reported a position in CASI Pharmaceuticals in Q2 2021 and held it in 1 quarter.
  • Y-Intercept (HK)'s CASI Pharmaceuticals position peaked at $25K in Q2 2021.
  • 58 funds tracked by Wall St. Rank held CASI Pharmaceuticals as of Q3 2021.

Based on Y-Intercept (HK)'s 13F filing for Q3 2021, filed 15 Nov 2021.